Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nordimaprit
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Nordimaprit is a histamine H2 receptor agonist that has demonstrated the ability to decrease tyrosinase activity in cultured human melanoma cells. This leads to a significant reduction and eventual loss of pigment. Its mechanism of action involves three components: the induction of an inhibitory activity against tyrosinase, an increased rate of tyrosinase degradation, and a long-term down-regulation of tyrosinase expression. The depigmenting effect was shown to be long-lasting, with cells remaining amelanotic for weeks after drug removal.
02
Targets
HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on nordimaprit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nordimaprit.